Global Cervical Cancer Market to grow at a CAGR of 4.87% during 2014-2019; Finds New Report

Report forecast the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.

Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells.

Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups. Vaginal bleeding and pelvic pain are usually observed as signs and symptoms of cervical cancer.

Before cancer detected in the cervix, cervix cells go through changes, called as dysplasia, in which abnormal cells start to expose in the cervical tissue. Over a period, the abnormal cells may developed into cancer cells and begin to grow and spread more deeply into the cervix and surrounding areas.

The report covers the current scenario and the growth prospects of the global cervical cancer market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment and prevention of cervical cancer.

Global Cervical Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cervical cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

According to the report, cancer drugs are expensive, and some individuals cannot afford chemotherapy. Reimbursement plans such as public reimbursement programs reduce the financial burden of treatment. The reimbursement status of drugs is dynamic in nature and varies across countries. Factors such as the lack of cost-effectiveness can impede the reimbursement coverage of drugs.

Key regions

• Americas
• APAC
• EMEA

Key players in the Global Cervical Cancer Market: F. Hoffmann-La Roche, GlaxoSmithKline and Merck

Other Prominent Vendors in the market are: Advaxis Immunotherapies, Bionor Pharma, Dendreon Corporation, Inovio Pharmaceuticals, ISA Pharmaceuticals, Otsuka Pharmaceuticals, Profectus Biosciences, Virometix and Zeria Pharmaceuticals

Key market driver

• Increase in incidence rate
• For a full, detailed list, view our report

Key market challenge

• Adverse effects of drugs and vaccines
• For a full, detailed list, view our report

Key market trend

• Patient assistance programs
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 70 pages “Global Cervical Cancer Market 2015-2019” report covers Executive Summary, Scope of the Report, Market Research Methodology, Introduction, Disease overview, Market landscape, Market segmentation by application, Market segmentation  by type of therapy, Geographical segmentation, Key brand analysis,  Pipeline portfolio, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For further information on this report, please visit- http://mrr.cm/ow3

Find all Oncology Reports at: http://www.marketresearchreports.com/oncology